Top Page
Benchmark Holdings
(LSE:BMK)
Benchmark Holdings (BMK) vs. iShares MSCI United Kingdom ETF (EWC)
Benchmark Holdings Business Overview & Revenue Model
Benchmark Holdings Financial Statement Overview
| Breakdown | |||||
| TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 67.61M | 90.36M | 169.48M | 158.28M | 125.06M | 105.56M | Gross Profit |
| 25.62M | 43.95M | 86.75M | 83.13M | 65.58M | 54.96M | EBIT |
| -35.89M | -35.50M | -5.32M | -4.76M | -1.01M | -7.68M | EBITDA |
| 5.78M | 3.96M | 34.20M | 28.35M | 24.36M | 14.34M | Net Income Common Stockholders |
| -41.76M | -39.46M | -23.15M | -30.45M | -11.58M | -22.77M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 13.81M | 23.09M | 36.52M | 36.40M | 39.46M | 71.61M | Total Assets |
| 380.77M | 384.90M | 471.30M | 526.57M | 481.99M | 489.04M | Total Debt |
| 75.84M | 72.07M | 102.00M | 110.14M | 120.39M | 109.16M | Net Debt |
| 62.03M | 48.98M | 65.47M | 73.74M | 80.93M | 37.55M | Total Liabilities |
| 155.33M | 160.63M | 188.68M | 203.29M | 202.39M | 193.59M | Stockholders Equity |
| 219.74M | 218.26M | 276.40M | 313.40M | 271.71M | 289.13M |
| Cash Flow | Free Cash Flow | ||||
| -6.50M | -1.92M | 13.22M | -1.91M | -16.93M | -15.47M | Operating Cash Flow |
| -2.72M | 2.00M | 20.00M | 10.81M | 5.79M | -4.06M | Investing Cash Flow |
| -2.81M | -2.83M | -5.27M | -11.22M | -23.09M | 30.38M | Financing Cash Flow |
| -4.05M | -10.97M | -12.33M | -6.92M | -14.67M | 30.13M |
Benchmark Holdings Technical Analysis
Benchmark Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | £195.93M | 5.27 | 33.70% | 1.41% | -0.17% | 2591.96% | |
62 Neutral | £42.69M | 63.40 | 0.80% | ― | -4.37% | ― | |
59 Neutral | £178.70M | ― | ― | -16.14% | -68.06% | ||
54 Neutral | $5.38B | 3.27 | -45.10% | 3.30% | 16.81% | 0.02% | |
51 Neutral | £314.59M | ― | -369.20% | ― | 4.50% | 74.32% |
Benchmark Holdings Corporate Events
Benchmark Holdings reported a £76 million profit for the first half of 2025, primarily driven by the £90.9 million gain from the sale of its Genetics business. The company plans to return capital to shareholders and delist from AIM and Euronext Growth Oslo. Despite a 22% decline in group revenues from continuing activities, the company has shown improvements in Advanced Nutrition and maintained solid performance in its Health segment. The restructuring following the Genetics sale is expected to streamline operations and reduce costs, positioning Benchmark for future growth. The company is also preparing for the relaunch of Ectosan® Vet and CleanTreat® with a new land-based model.
Benchmark Holdings plc has announced a change in the timing of its Equity Development webcast for retail investors, which will now occur at 10.00am UK time on Thursday, 12 June 2025. This webcast is part of the company’s release of its unaudited interim results for the six-month period ending 31 March 2025. The change in schedule reflects the company’s commitment to engaging with its investors and stakeholders, potentially impacting investor relations and market perception.
Benchmark Holdings plc has announced that it will release its unaudited interim results for the six-month period ending 31 March 2025 on 12 June 2025. The announcement will be accompanied by presentations for analysts, institutional investors, retail investors, and wealth managers, indicating the company’s commitment to transparency and engagement with its stakeholders.
Benchmark Holdings PLC has announced a series of proposals following the disposal of its Genetics Business, including the return of capital to shareholders and the cancellation of its shares from trading on AIM and Euronext Growth Oslo. The company plans to re-register as a private limited company and offer a tender for shareholders to realize their investments, with a special dividend planned post-tender. These moves aim to streamline operations and focus on future growth, with implications for shareholder structure and market presence.
Benchmark Holdings PLC announced that as of 30 April 2025, its issued share capital consists of 741,505,672 ordinary shares, all with voting rights. This figure has remained unchanged since the previous announcement on 31 March 2025, and shareholders can use this number to calculate their interest in the company. This stability in share capital indicates a steady state in the company’s financial structure, which could reassure investors and stakeholders about the company’s current market position.
Benchmark Holdings has announced the completion of its Green Bond redemption and repayment of its RCF, making the company debt-free. The company has also streamlined its corporate structure following the sale of its Genetics division, preparing for its next phase of operations. Details on the strategy for continuing business and return of capital are expected in May, signaling a strategic shift that could impact its market positioning and stakeholder interests.
Benchmark Holdings PLC announced its decision to exercise a call option to redeem all outstanding bonds from its senior unsecured bond issue, originally set to mature in September 2025. This strategic financial move, scheduled for completion by April 15, 2025, is expected to impact the company’s financial structure by addressing its debt obligations earlier than planned, potentially enhancing its market position and stakeholder confidence.
Benchmark Holdings has completed the sale of its genetics business to Starfish Bidco, a subsidiary of Novo Holdings, for an enterprise value of £260 million. This transaction is expected to yield gross cash proceeds of approximately £194 million, with net cash proceeds of about £107.5 million after debt repayments. The sale aligns with Benchmark’s strategic focus, and further details on the use of proceeds will be provided in mid-April.
Benchmark Holdings plc announced an update on its total voting rights, reporting an issued share capital of 741,505,672 ordinary shares as of March 31, 2025. This increase in shares, attributed to the routine exercise of options by employees, impacts the calculation for shareholders to notify changes in their interest in the company.